Observational study / 2014
In patients with Crohn's disease, cannabis use for over 6 months was linked to an increased risk of requiring surgery despite reported symptom relief.
A structured anonymous questionnaire was completed by 313 consecutive patients with IBD to evaluate motives, patterns, and outcomes of cannabis use. Overall, 17.6% used cannabis specifically for IBD symptoms (96.4% via inhalation), reporting improvements in abdominal pain (83.9%), abdominal cramping (76.8%), joint pain (48.2%), and diarrhea (28.6%), though side effects were frequent. After adjusting for demographic factors, smoking status, time since diagnosis, and biological use, cannabis use for more than 6 months was a strong predictor of requiring surgery in Crohn's disease patients (OR = 5.03, 95% CI = 1.45-17.46), but was not a predictor for hospitalization in the previous year.
Shows an association, not proof of cause and effect.
- Study type
- Cross-sectional survey study
- Who was studied
- 313 consecutive patients with inflammatory bowel disease (IBD)
- What was measured
- Motives, subjective effects of cannabis, and risk of surgery or hospitalization
THE PAPER
Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.
Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Inflamm Bowel Dis, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.